Meeting
2023 ASCO Annual Meeting
A phase 3 multicenter study to evaluate the safety and efficacy of padeliporfin vascular targeted photodynamic therapy (VTP) in treatment of low-grade (LG) upper tract urothelial cancer (UTUC).
Authors
Jonathan Coleman
Memorial Sloan Kettering Cancer Center, New York, NY
Jonathan Coleman , Vitaly Margulis , Avigdor Joshua Scherz , Inna Krasnopolskaya , Genia Alpert , Veronique Jobert , Dina Preise , Neal D. Shore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT04620239
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4613)
DOI
10.1200/JCO.2023.41.16_suppl.TPS4613
Abstract #
TPS4613
Poster Bd #
99a
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Treatment results from a phase I study of WST11 phototherapy (VTP) for upper tract urothelial carcinoma.
First Author: Lucas Nogueira
Poster
2024 ASCO Annual Meeting
A phase 1/2 dose escalation and expansion study of sonodynamic therapy with SONALA-001 in combination with Exablate 4000 Type 2.0 MR-guided focused ultrasound in patients with progressive or recurrent glioblastoma (rGBM).
First Author: Dimitris Placantonakis
Poster
2013 ASCO Annual Meeting
Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): A phase I study.
First Author: Haruko Daga
Poster
2024 ASCO Annual Meeting
H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).
First Author: Stephen R. D. Johnston